Cargando…
Transplantation of Apoptosis‐Resistant Endothelial Progenitor Cells Improves Renal Function in Diabetic Kidney Disease
BACKGROUND: Diabetic kidney disease is associated with glomerulosclerosis and poor renal perfusion. Increased capillary formation and improved perfusion may help to halt or reverse the injury. Transplanting apoptosis‐resistant p53‐silenced endothelial progenitor cells (p53sh‐EPCs) may help improve v...
Autores principales: | Kundu, Nabanita, Nandula, Seshagiri R., Asico, Laureano D., Fakhri, Mona, Banerjee, Jaideep, Jose, Pedro A., Sen, Sabyasachi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174326/ https://www.ncbi.nlm.nih.gov/pubmed/33759548 http://dx.doi.org/10.1161/JAHA.120.019365 |
Ejemplares similares
-
Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes
por: Nandula, Seshagiri Rao, et al.
Publicado: (2021) -
Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial
por: Awal, Hassan B., et al.
Publicado: (2020) -
Cardiovascular disease (CVD) risk assessment of HIV medication regimens using hematopoietic CD34+ progenitor cells
por: Elzarki, Adrian Farid, et al.
Publicado: (2022) -
Comparison Between Linagliptin and Canagliflozin Effect on Inflammatory Markers, CD34+ Cell Gene Expression and Urine Exosomes in Type 2 Diabetes Subjects
por: Nandula, Seshagiri R, et al.
Publicado: (2021) -
Use of p53‐Silenced Endothelial Progenitor Cells to Treat Ischemia in Diabetic Peripheral Vascular Disease
por: Kundu, Nabanita, et al.
Publicado: (2017)